PCM Task Force Chair: Andreas Lundqvist, tumor immunologist
Cancer immunotherapy, by targeting immunological checkpoints or engineering of lymphocytes for adoptive cell therapy, provide an unprecedented level of long-term anti-tumor activity in patients with metastatic cancer. However the majority of patients with advanced cancers still do not experience sustained clinical benefit from immunotherapy. As such, there is a growing demand to perform immune profiling in order to understand the mechanistic basis of response and resistance to these therapies. Following an inventory of activities and facilities in the research area of tumor immunology at KI/K, the Task Force identified the need for exploratory and tailored immune profiling. The vision is to create better conditions for collaborations for pre-clinical and clinical research in tumor immunology.